Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970

505.64 +3.33 +0.66%

Live - 5344 symbols - heartbeat 405s ago · 2026-10-08 08:19

Pre-market 506.67 +0.20%

After-hours 505.80 +0.03%

Overnight 505.01 -0.12%

Market cap: 128.16B
P/E (TTM): 29.45
P/B: 6.33
EPS: 15.32
Div yield: 0.00%
52W pos: 65%

Reader sentiment Are you bullish or bearish on VRTX?

Anonymous reader poll. Unscientific, not investment advice.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Founded: 1989
CEO: Dr. Reshma Kewalramani, M.D.
Employees: 6,400
Headquarters: Boston, Massachusetts, United States of America
Fiscal year end: 12-31
Website: vrtx.com

Company profile

Exchange: US
Symbol: VRTX
Market-cap rank: #155
Listing date: 1970-01-01
Market cap: 128.16B
Float cap: 127.77B
Shares out: 253.46M
Float shares: 252.68M

Sectors & themes

Biotechnology ARK Portfolio Gene Editing Global medical industry Regular Savings Plan Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:19:31 · For reference only, not investment advice and not tailored to your situation.